Results 51 to 60 of about 11,782,455 (235)

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Pathohistological characteristics of steatohepatitis on needle biopsy sample from 100 patients [PDF]

open access: yesMedicinski Podmladak, 2019
Introduction: Steatohepatitis is a form of fatty liver disease, in which there is a deposit of fat and steatosis which occurs in two forms: alcoholic and non-alcoholic fatty liver disease.
Milićević Anđela   +2 more
doaj  

Machine learning to predict progression of non‐alcoholic fatty liver to non‐alcoholic steatohepatitis or fibrosis

open access: yesJGH Open, 2022
Background Non‐alcoholic fatty liver (NAFL) can progress to the severe subtype non‐alcoholic steatohepatitis (NASH) and/or fibrosis, which are associated with increased morbidity, mortality, and healthcare costs.
Sina Ghandian   +7 more
doaj   +1 more source

Rapid development of non-alcoholic steatohepatitis in Psammomys obesus (Israeli sand rat). [PDF]

open access: yesPLoS ONE, 2014
BACKGROUND AND AIMS: A major impediment to establishing new treatments for non-alcoholic steatohepatitis is the lack of suitable animal models that accurately mimic the biochemical and metabolic characteristics of the disease.
Briana Spolding   +16 more
doaj   +1 more source

Role of silymarin in the management of deranged liver function in non-alcoholic steatohepatitis: a case report

open access: yesDrugs in Context, 2023
Non-alcoholic fatty liver disease is one of the main causes of elevated liver enzymes and chronic liver disease worldwide. It ranges from steatosis to steatohepatitis, leading to cirrhosis and related liver dysfunction.
Yeong Yeh Lee, Vincent Tee
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists in Multiple Sclerosis: A Topical Narrative Review

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT The glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are a relatively new class of drugs that were initially approved by the US Food and Drug Administration to improve glycemic control in patients with type 2 diabetes mellitus and, subsequently, weight reduction in patients with obesity.
Audrey Y. Chang, Farrah J. Mateen
wiley   +1 more source

Changes in direct markers of liver fibrosis in patients with steatohepatitis non-alcoholic and alcoholic origin on the background of obesity and pathology of the biliary tract

open access: yesZaporožskij Medicinskij Žurnal, 2017
The aim of this work is to investigate the direct markers of liver fibrosis (LF) in patients with steatohepatitis non-alcoholic and alcoholic origin in combination with obesity (OB) and pathology of the biliary tract (BT). Materials and Methods.
A. Yu. Filippova
doaj   +1 more source

Drug Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Fibrosis

open access: yesРоссийский журнал гастроэнтерологии, гепатологии, колопроктологии, 2022
Aim. An overview of current pharmacotherapy for non-alcoholic steatohepatitis (NASH)-associated liver fibrosis.Key points. In current clinical recommendations, therapeutic measures in non-alcoholic fatty liver disease should include lifestyle change ...
D. V. Garbuzenko
doaj   +1 more source

Rab1A Promotes Hepatic Steatosis by Suppressing Mitophagy via the Raf‐1/ERK1/2/PINK1 Signaling Axis

open access: yesAdvanced Science, EarlyView.
Why does fat accumulate in the liver? Our study reveals Rab1A as the molecular switch that silences the cell's mitochondrial cleanup crew. Turning Rab1A off reactivates mitophagy, clears excess fat, and reverses fatty liver disease in mice—offering a promising new therapeutic target for MASLD, a growing global health challenge.
Li Zhang   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy